Coxsackievirus A16 induced neurological disorders in young gerbils which could serve as a new animal model for vaccine evaluation.
Coxsackievirus A16 (CA16) is one of the major pathogens associated with human hand, foot, and mouth disease (HFMD) in the Asia-pacific region. Although CA16 infections are generally mild, severe neurological manifestations or even death has been reported. Studies on CA16 pathogenesis and vaccine development are severely hampered because the small animal models that are currently available show major limitations. In this study, gerbils (Meriones unguiculatus) were investigated for their suitability as an animal model to study CA16 pathogenesis and vaccine development. Our results showed that gerbils up to the age of 21 days were fully susceptible to CA16 and all died within five days post-infection. CA16 showed a tropism towards the skeletal muscle, spinal cord and brainstem of gerbils, and severe lesions, including necrosis, were observed. In addition, an inactivated CA16 whole-virus vaccine administrated to gerbils was able to provide full protection to the gerbils against lethal doses of CA16 strains. These results demonstrate that gerbils are a suitable animal model to study CA16 infection and vaccine development.
Key Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Yi-Sheng
YS
Sun
Sinovac Biotech Co., Ltd., Beijing, China.
Ya-Jing
YJ
Li
Key Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Yong
Y
Xia
Key Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Fang
F
Xu
Sinovac Biotech Co., Ltd., Beijing, China.
Wei-Wei
WW
Wang
Key Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Zhang-Nv
ZN
Yang
Key Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Hang-Jing
HJ
Lu
Key Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Zhi-Ping
ZP
Chen
Key Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Zi-Ping
ZP
Miao
The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Wei-Feng
WF
Liang
Central Lab of Biomedical Research Center, Sir Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Zhi-Yao
ZY
Xu
Ningbo Municipal Center for Disease Control and Prevention, Ningbo, China.
Hong-Jun
HJ
Dong
Taizhou Municipal Center for Disease Control and Prevention, Taizhou, China.
Dan-Hong
DH
Qiu
Key Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Zhi-Yong
ZY
Zhu
Department of Microbiology and Parasitology, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, School of Medicine, Zhejiang University, Hangzhou, China.
Stijn
S
van der Veen
College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
Jie
J
Qian
College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
Bin
B
Zhou
Key Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Ping-Ping
PP
Yao
Key Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Han-Ping
HP
Zhu
PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2599
24367714
Med Microbiol Immunol. 2010 Feb;199(1):45-51
19941005
Southeast Asian J Trop Med Public Health. 2015 May;46(3):449-59
26521518
Vaccine. 2013 Apr 26;31(18):2215-21
23499596
J Virol. 2012 Nov;86(22):11967-76
22951825
Vaccine. 2015 Sep 22;33(39):5087-94
26296491
Arch Pharm Res. 2015 Feb;38(2):193-202
24752860
Emerg Microbes Infect. 2015 Feb;4(2):e12
26038764
Virus Res. 2014 Jan 22;179:212-9
24211607
Vaccine. 2014 May 1;32(21):2406-12
24657161
Emerg Infect Dis. 2007 Jul;13(7):1084-6
18214187
PLoS One. 2012;7(12):e51996
23284845
Rev Med Virol. 2015 Mar;25(2):115-28
25704797
PLoS One. 2015 Mar 13;10(3):e0119173
25767882
J Gen Virol. 2014 May;95(Pt 5):1083-93
24496826
PLoS One. 2014 Oct 28;9(10):e111174
25350381
N Engl J Med. 1963 May 9;268:1041-4
14001956
Infect Immun. 1984 Jan;43(1):43-8
6690414
BMC Infect Dis. 2013 Dec 27;13:606
24370001
Ann Acad Med Singapore. 2009 Feb;38(2):106-12
19271036
Viruses. 2014 Jul 17;6(7):2778-95
25036464
J Virol. 2014 Jun;88(11):6444-52
24672036
J Med Virol. 2015 Dec;87(12):2009-17
26010334
Chin Med J (Engl). 1986 Sep;99(9):760-2
3100239
J Virol. 2004 Aug;78(15):7916-24
15254164
Clin Infect Dis. 2007 Mar 1;44(5):646-56
17278054
Parasit Vectors. 2014 Jan 22;7:43
24450869
J Virol. 2010 Jan;84(1):661-5
19864378
Emerg Infect Dis. 2009 Oct;15(10):1689-91
19861078
PLoS One. 2014 Apr 28;9(4):e96051
24776922
Virol J. 2011 Mar 08;8:106
21385398
Antiviral Res. 2016 May;129:47-51
26902108
Clin Lab. 2011;57(11-12):959-67
22239028
Jpn J Infect Dis. 2009 Jul;62(4):254-9
19628900
Virus Res. 2012 Jul;167(1):86-96
22575826
Microbes Infect. 2011 Sep;13(10):862-70
21612764
Pediatr Infect Dis J. 2004 Mar;23(3):275-6
15014311
Vaccine. 2014 Jul 23;32(34):4296-303
24950363
Lancet. 2013 Mar 23;381(9871):1037-45
23352749
Pediatr Infect Dis J. 1999 Dec;18(12):1092-6
10608631
J Clin Microbiol. 2010 Feb;48(2):619-22
20018819
Scand J Infect Dis. 2012 Apr;44(4):297-305
22176514
Expert Rev Vaccines. 2016 May;15(5):599-606
26732723